Epithalon

What it is

Epithalon (also spelled Epitalon) is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly, or AEDG) created by Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology as a simplified version of Epithalamin, a natural bovine pineal gland extract. It is best known for claims that it activates telomerase and slows aging, but the evidence for this is thin and comes almost entirely from that one research group. The original 2003 finding that Epithalon activates telomerase and lengthens telomeres was done in cultured human fibroblasts in a dish, not in living people. In mice and fruit flies, the same group has reported modest lifespan extension. A 2025 study from Brunel University London independently replicated the telomerase and telomere-lengthening effect in normal human cell lines in vitro, which is a genuine positive sign, but that same study found a different, potentially concerning telomere-maintenance activation pathway in cancer cell lines. No published human clinical trial has tested the synthetic Epithalon peptide itself for safety, dosing, or anti-aging outcomes; separate elderly-mortality data sometimes cited for it actually studied Epithalamin, the related natural pineal extract, not the synthetic Epithalon peptide. Epithalon is not FDA- or EMA-approved and has no listing in DailyMed. In July 2026 an FDA advisory committee did vote to recommend adding Epitalon to the Section 503A Bulks List (the list of substances pharmacies may compound), evaluated for insomnia rather than longevity, but that recommendation is nonbinding and does not make it an approved drug or, by itself, legal to compound; see our peptide regulation tracker for the dated detail.

Dose ranges

Study-backed ranges carry a source you can open. Community ranges are widely reported but not clinically established - treat them as what people do, not as advice.

Reconstitution & storage

Community (vendor/forum) protocols commonly reconstitute 10 mg vials with 1-2 mL bacteriostatic water for roughly 5-10 mg/mL. No clinical or manufacturer-standard reconstitution protocol exists because Epithalon has no approved formulation; all reconstitution guidance found is community-sourced.

Interactions & cautions

No drug-drug or peptide-drug interaction studies of Epithalon exist in humans or animals; this section cannot be sourced beyond noting the absence of data. A separate biological caution is worth flagging: an independent 2025 in vitro replication (Al-Dulaimi et al., Biogerontology) that confirmed telomerase upregulation and telomere lengthening by Epitalon in normal human cell lines also found that in breast cancer cell lines (21NT, BT474), Epitalon increased telomere length primarily via activation of the alternative lengthening of telomeres (ALT) pathway rather than telomerase, with no significant net increase in telomerase enzyme activity in those cancer lines. Because unregulated telomere-maintenance activation (via either telomerase or ALT) is a recognized hallmark of cancer biology, this is a genuine, source-grounded reason for caution rather than a hypothetical one, even though no human carcinogenicity data exist either way.

Questions people ask

Sources

1. [1]Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells (Khavinson, Bondarev, Butyugov, 2003, Bull Exp Biol Med) PMID 12937682studyOriginal foundational finding: adding Epithalon to telomerase-negative human fetal fibroblast cultures induced telomerase catalytic subunit expression, enzymatic telomerase activity, and telomere elongation, in vitro.
2. [2]Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (Al-Dulaimi, Thomas, Matta, Roberts, 2025, Biogerontology) PMID 40908429studyIndependent (Brunel University London) in vitro replication: confirms telomerase-mediated telomere lengthening in normal human cell lines (fibroblasts, epithelial cells), but finds ALT-pathway (not telomerase) activation with no net telomerase increase in breast cancer cell lines -- the basis for the cancer-related caution note.
3. [3]Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (2025, Biogerontology) PMID 41240216studyPublished erratum confirming the correction to the Al-Dulaimi 2025 paper was limited to replacing incorrect versions of Figures 1-3; no textual conclusions were retracted.
4. [4]Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties (Araj, Brzezik, Madra-Gackowska, Szeleszczuk, 2025, Int J Mol Sci) PMID 40141333reviewComprehensive 25-year literature review confirming: AEDG chemical identity; that essentially all in vivo evidence is animal-only (mouse, rat, Drosophila) at microgram subcutaneous doses; that no human clinical efficacy or safety trial of Epithalon has been published; and that physico-chemical/mechanistic data remain limited.
5. [5]Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes (Khavinson et al., 2019, Bull Exp Biol Med) PMID 31761987studySmall ex vivo study (blood lymphocytes from 11 men, ages 18-22 and 49-54) treated with AEDG peptide in culture: found telomere-length changes (both increases and decreases) in 7 of 11 subjects' samples, described by the authors as 'a tendency to normalization' rather than a uniform increase -- used to correct the stronger 'clinical trial in patients aged 60-80' claim repeated on vendor sites, which this paper does not support.
6. [6]Peptides of pineal gland and thymus prolong human life (Khavinson & Morozov, 2003, Neuroendocrinology Letters)studyA follow-up of 193-266 elderly subjects given Thymalin and/or Epithalamin (the natural pineal/thymic extracts, NOT the synthetic Epithalon tetrapeptide) reported reduced mortality over 6-8 years; cited here only to document that this frequently-referenced 'human longevity data' concerns a different, related compound, not to support efficacy claims about synthetic Epithalon itself.
7. [7]DailyMed search results for 'epithalon'regulatoryConfirms zero FDA drug product labels exist for Epithalon/Epitalon, i.e. it has no FDA-approved formulation.
8. [8]PubChem Compound Summary for CID 219042, EpitalonreferenceConfirms chemical identity: molecular formula C14H22N4O9, consistent with the AEDG (Ala-Glu-Asp-Gly) tetrapeptide structure.
9. [9]FDA advisory committee nominates six peptides for pharmacies to compound (NCPA, 2026)regulatoryReports that on July 23-24, 2026 the FDA Pharmacy Compounding Advisory Committee recommended six of seven reviewed peptides (including Epitalon) for the 503A Bulks List, that the recommendation is nonbinding, that the HHS Secretary must formally approve, and that pharmacies may not compound them until final rulemaking is in place; the basis for the 2026 regulatory-status note and FAQ.